↓ Skip to main content

Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study

Overview of attention for article published in Journal of Orthopaedic Surgery and Research, December 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#31 of 1,352)
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog

Citations

dimensions_citation
92 Dimensions

Readers on

mendeley
161 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study
Published in
Journal of Orthopaedic Surgery and Research, December 2017
DOI 10.1186/s13018-017-0689-6
Pubmed ID
Authors

Mahasen Al-Najar, Hiba Khalil, Jihad Al-Ajlouni, Eman Al-Antary, Mohammad Hamdan, Reem Rahmeh, Dana Alhattab, Osama Samara, Mohamad Yasin, Amenah Al Abdullah, Esraa Al-jabbari, Dima Hmaid, Hanan Jafar, Abdalla Awidi

Abstract

Knee osteoarthritis (KOA) is a major health problem especially in the aging population. There is a need for safe treatment that restores the cartilage and reduces the symptoms. The use of stem cells is emerging as a possible option for the moderate and severe cases. This study aimed at testing the safety of autologous bone marrow mesenchymal stem cells (BM-MSCs) expanded in vitro when given intra-articularly to patients with stage II and III KOA. As a secondary end point, the study tested the ability of these cells to relieve symptoms and restore the knee cartilage in these patients as judged by normalized knee injury and Osteoarthritis Outcome Score (KOOS) and by magnetic resonance imaging (MRI). Thirteen patients with a mean age of 50 years suffering from KOA stages II and III were given two doses of BM-MSCs 1 month apart totaling 61 × 106 ± 0.6 × 106 by intra-articular injection in a phase I prospective clinical trial. Each patient was followed for a minimum of 24 months for any adverse events and for clinical outcome using normalized KOOS. Cartilage thickness was assessed by quantitative MRI T2 at 12 months of follow-up. No severe adverse events were reported up to 24 months follow-up. Normalized KOOS improved significantly. Mean knee cartilage thickness measured by MRI improved significantly. BM-MSCs given intra-articularly are safe in knee osteoarthrosis. Despite the limited number of patients in this study, the procedure described significantly improved the KOOS and knee cartilage thickness, indicating that they may enhance the functional outcome as well as the structural component. ClinicalTrials.gov, NCT02118519.

Mendeley readers

The data shown below were compiled from readership statistics for 161 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 161 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 29 18%
Student > Bachelor 27 17%
Student > Master 18 11%
Student > Ph. D. Student 14 9%
Student > Doctoral Student 8 5%
Other 26 16%
Unknown 39 24%
Readers by discipline Count As %
Medicine and Dentistry 47 29%
Biochemistry, Genetics and Molecular Biology 20 12%
Agricultural and Biological Sciences 9 6%
Engineering 7 4%
Nursing and Health Professions 6 4%
Other 26 16%
Unknown 46 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2022.
All research outputs
#1,558,467
of 22,581,456 outputs
Outputs from Journal of Orthopaedic Surgery and Research
#31
of 1,352 outputs
Outputs of similar age
#43,059
of 450,100 outputs
Outputs of similar age from Journal of Orthopaedic Surgery and Research
#3
of 139 outputs
Altmetric has tracked 22,581,456 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,352 research outputs from this source. They receive a mean Attention Score of 3.4. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,100 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 139 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.